leisure time -WSS

leisure time

author：comprehensive 2025-08-12 09:11:53 - browse：74172

JOSEPH PREZIOSO/AFP via Getty Images

LONDON — The U.K.’s cost-effectiveness watchdog said Thursday it is not yet recommending Vertex’s CRISPR-based therapy for sickle cell disease, saying in draft guidance it has questions about the medicine’s lasting benefits for patients.

U.K. regulators approved the therapy, known as Casgevy or exa-cel, last year, granting it the world’s first authorization for any CRISPR-based medicine. But observers have been watching to see how the U.K.’s National Institute for Health and Care Excellence, as well as similar agencies in European countries, would view the pricey, one-time therapy. NICE needs to recommend the therapy for it to be offered in the National Health Service.

In the U.S., Casgevy has a list price of $2.2 million. It was developed by Vertex in partnership with CRISPR Therapeutics.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How to save PrEP access — and even expand it
Next article： US judge blocks portions of new Florida elections law

entertainment

hotspot

WSS

Cytokinetics CEO Robert Blum is on my Worst CEO shortlist again

NASA releases new images of 'fingerprint

Making the case for fair compensation in clinical trials

US judge blocks portions of new Florida elections law

Digital health: a case of mistaken identity

July 4th fireworks can be stressful for dogs. These 6 tips can keep them calm and safe

hotspot

leisure time

explore

How to save PrEP access — and even expand it

Kremlin open to talks over potential prisoner swap involving detained US reporter Evan Gershkovich

ChatGPT in medicine: STAT answers readers' burning questions

UnitedHealth argues against case alleging wrongful AI care denials

Heart attack and stroke risk calculators need revising

Scrutiny of post

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Readout Newsletter: Eli Lilly, AstraZeneca, Bristol Meyers Squibb

Duchenne breakthrough therapy leaves behind pioneering families

FDA poised to publish guidelines for clinical trial diversity

entertainment

For longer

The Democratic Party promised to overhaul its primaries. Doing that has been anything but simple

Greece's new parliament sworn in following conservative party's election victory

1 dead, 9 hurt in July 4th fireworks explosion

US judge blocks portions of new Florida elections law

4 dead, 2 in stable condition in Philadelphia shooting: Police

entertainment

hotspot

entertainment

focus